Is the combination synergistic?

Not established. Synergy requires a factorial design measuring each agent alone and together, and no such demonstration exists for this pairing.

What is the difference between additive and synergistic?

Additive means the effects sum; synergistic means the combination exceeds the sum. The second is a stronger claim needing stronger evidence.

Is the rationale worthless then?

No. Real receptor non-overlap is a good reason to test the combination, better than most pairings have. It is not evidence of the result.

Is the CJC-1295 and Ipamorelin Combination Synergistic?

The short answer

Synergy has a precise meaning (a combined effect exceeding the sum of the individual effects), and demonstrating it requires measuring each agent alone and together. The mechanistic rationale for this pairing is sound; the synergy claim specifically has not been established that way.

Key facts

Additive: Combined effect equals the sum
Synergistic: Combined effect exceeds the sum
Required to show either: Single-agent arms plus combination
Rationale here: Real receptor non-overlap
Demonstration: Not established by a factorial design
Worked example elsewhere: REDEFINE 1 for CagriSema

The words are not interchangeable

Additive means two effects sum. Synergistic means the combination exceeds the sum: the agents make each other more effective. Synergy is a stronger claim and requires more evidence, and the words are used loosely in commercial writing in a way that inflates what has been shown.

What a study would need

Four conditions: agent A alone, agent B alone, both together, and neither. Without the single-agent arms there is no baseline to compare the combination against, so no statement about additivity or synergy is possible. This is the standard factorial design for any combination question and it is not exotic.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

The example from the incretin field

REDEFINE 1 tested CagriSema against cagrilintide alone, semaglutide alone and placebo, which is the design described above. That is what allowed a claim that the combination outperformed its components. The contrast with the CJC-1295 and ipamorelin literature is instructive: the same question, one answered properly and one not.

Why the rationale is still worth something

Real receptor non-overlap makes additivity plausible in a way that combining two compounds with unclear mechanisms does not. It is a reason to test the combination, and a better reason than most pairings in this field have. It is not a substitute for having tested it.

How to read combination claims generally

Ask what the comparison was. A combination producing a large effect proves nothing about the combination unless each component was measured separately in the same experiment. That single question resolves most claims of this kind, here and elsewhere.

Frequently asked questions

Is the combination synergistic?: Not established. Synergy requires a factorial design measuring each agent alone and together, and no such demonstration exists for this pairing.
What is the difference between additive and synergistic?: Additive means the effects sum; synergistic means the combination exceeds the sum. The second is a stronger claim needing stronger evidence.
Is the rationale worthless then?: No. Real receptor non-overlap is a good reason to test the combination, better than most pairings have. It is not evidence of the result.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
▸Ghrelin-receptor binding assays for Ipamorelin analogue development
▸Analytical HPLC method development for lipidated GHRH analogues
▸Stability testing under refrigerated storage

Handling checklist

✓Store lyophilised at −20 °C long-term
✓Reconstitute in bacteriostatic water; both peptides dissolve readily
✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Synergy: A Word Worth Using Carefully